Journal
AUTOIMMUNITY REVIEWS
Volume 16, Issue 6, Pages 658-665Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2017.04.010
Keywords
Relapsing-remitting multiple sclerosis; Disease modifying therapy; Natalizumab; Fingolimod; Alemtuzumab; Systematic review
Categories
Funding
- Multiple Sclerosis Society (UK) [46]
- National Health and Medical Research Council [1083539, 1032484, 1129189, 1080518, 1001216]
- University of Melbourne [Faculty of Medicine, Dentistry and Health Sciences research fellowship]
- Czech Ministry of Education [PRVOUK-P26/LF1/4]
- National Health and Medical Research Council of Australia [1129189] Funding Source: NHMRC
Ask authors/readers for more resources
Background: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. One can therefore speculate that early initiation of highly effective immunotherapies, with an average efficacy that is superior to the typical first-line therapies, could further improve relapse and disability outcomes. However, the most common treatment strategy is to commence firstline therapies, followed by treatment escalation in patients who continue to experience on-treatment disease activity. While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider high-efficacy treatment strategies from disease onset (including induction therapy) in order to prevent irreversible disability. Objective: In this systematic review, we evaluate the effect of high-efficacy immunotherapies at different stages of MS. Methods: A systematic review of literature reporting outcomes of treatment with fingolimod, natalizumab or alemtuzumab at different stages of MS was carried out. Results and conclusions: Twelve publications reporting relevant information were included in the systematic review. The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay after the MS diagnosis. The evidence reported for disability and MRI outcomes is inconclusive. (C) 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available